Lexeo shares positive data in trial of LX2006 for FA cardiomyopathy - Ataxia UK

Lexeo shares positive data in trial of LX2006 for FA cardiomyopathy

Post Published: October 8, 2025

The pharmaceutical company Lexeo Therapeutics has announced positive updates from their phase I/II trial of the gene therapy LX2006 to treat cardiomyopathy in Friedreich’s ataxia (FA).  

Interim data has shown sustained or deepening improvements in most participants across both cardiac and neurological measures of FA.

This includes clinically meaningful improvement in the modified Friedreich Ataxia Rating Scale (mFARS), showing a slowed disease progression and improved function.

Following this, Lexeo are in discussions with the FDA about an accelerated approval pathway for LX2006.

Read the press release here.

Read more about the trial here.

Subscribe To Our Newsletter

fundraise image

FUNDRAISE FOR US

Take part in a challenge or create your fundraiser. Every penny you raise will help those affected by ataxia.

Donate Image

DONATE

To make either a one off or recurring donation which will help fund research into treatments and cures and supports those affected ataxia

Volunteer Image

VOLUNTEER WITH US

Support the ataxia community and volunteer with Ataxia UK. From social media to telephone befriending, there are loads of ways you can make a difference to someone's life.

Scroll to Top